Second-generation (also known as atypical) antipsychotics are increasingly used as adjunctive therapy for patients with major depressive disorder who have an inadequate or partial response to antidepressants. This course reviews the clinical rationale for their use, highlights newly approved options, and examines key safety, efficacy, and monitoring considerations. You will gain practical guidance to support patient selection, counseling, and shared decision-making when these agents are incorporated into depression management.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Sarah Grady, PharmD, BCPS, BCPP
Professor of Pharmacy Practice, Clinical Pharmacist
Drake University/Broadlawns Medical Center

GET CE FOR LISTENING!
Stay Compliant. Grow Clinically. Practice with Confidence. 

Pharmacist CE Subscription: All your CE in one convenient subscription. 

All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there’s even more!

What the Subscription Includes:

The Pharmacist CE Subscription includes: 

·       Compliance and licensure CE 

·       GameChangers Clinical Updates 

·       Practical continuing education across patient care topics 

*The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. 

Purchase Now!

PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription.

 
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here. 

 CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Explain the role of second-generation (atypical) antipsychotics as adjunctive therapy in the management of major depressive disorder.
2. Identify pharmacist-relevant considerations for counseling, monitoring, and risk benefit assessment when second-generation antipsychotics are used for depression.

Rachel Maynard and Sarah Grady have no relevant financial relationships to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-059-H01-P
Initial release date: 3/16/2026
Expiration date: 3/16/2027
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram